Refers to Oxadiazoles compounds of formula (i) wherein R1 and R2 together with the carbon Atom to which together form a Ring carbociclico (C3 - C10) or a Heterocyclic Ring of 5 to 11 members optionally substituted alkyl or Halogen (C1 - C6) heteroaryl R3 is 5 to 11 Member S optionally substituted with alkyl (C1 - C5), CN, amino, among others R4 is H, halogen,Alkyl (C1 - C3) or Nitrile R5 (C1 - C6) is alkyl, aryl, heteroaryl 5 to 11 members, among others.Preferred compounds are: 4 - [5 - (3 - [1 - [6 - (2 - aminopirimidin - 5 - il) pyridin-3-yl] cyclobutyl} - 1,2,4 - Oxadiazoles - 5 - il) pyridin-2-yl] - 1 - piperazin ter Butyl carboxylate n - 2 - 5 - [(3 - [1 - [6 - (2 - aminopirimidin - 5 - il) pyridin-3-yl] cyclobutyl} - 1,2,4 - Oxadiazoles - 5 - il) pyridin-2-yl] glycinamide 5 - [5 - (1 - {5 - [6 - (piperazin - 1 - il) pyridin-3-yl] - 1,2,4 - Oxadiazoles - 3 - il} cyclobutyl) pyridin-2-yl] pyrimidine 2 Amine among others.It also relates to a Pharmaceutical composition. These compounds are inhibitors of the 5-lipoxygenase Activating Protein (flap) being useful in the treatment of disorders mediated by leukotrienes such as atherosclerosisSE REFIERE A COMPUESTOS DERIVADOS DE OXADIAZOL DE FORMULA (I) DONDE R1 Y R2 JUNTO CON EL ATOMO DE CARBONO A LOS QUE SE UNEN FORMAN UN ANILLO CARBOCICLICO(C3-C10) O UN ANILLO HETEROCICLICO DE 5 A 11 MIEMBROS OPCIONALMENTE SUSTITUIDOS CON ALQUILO(C1-C6) O HALOGENO R3 ES HETEROARILO DE 5 A 11 MIEMBROS OPCIONALMENTE SUSTITUIDO CON ALQUILO(C1-C5), CN, AMINO, ENTRE OTROS R4 ES H, HALOGENO, ALQUILO(C1-C3) O NITRILO R5 ES ALQUILO(C1-C6), ARILO, HETEROARILO DE 5 A 11 MIEMBROS, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-[5-(3-{1-[6-(2-AMINOPIRIMIDIN-5-IL)PIRIDIN-3-IL]CICLOBUTIL}-1,2,4-OXADIAZOL-5-IL)PIRIDIN-2-IL]PIPERAZIN-1-CARBOXILATO DE TER-BUTILO N-2-[5-(3-{1-[6-(2-AMINOPIRIMIDIN-5-IL)PIRIDIN-3-IL]CICLOBUTIL}-1,2,4-OXADIAZOL-5-IL)PIRIDIN-2-IL]GLICINAMIDA 5-[5-(1-{5-[6-(PIPERAZIN-1-IL)PIRIDIN-3-IL]-1,2,4-OXADIAZOL-3-IL}CICLOBUTIL)PIRIDIN-2-
